In both phase 3 trials, onabotulinumtoxinA significantly improved platysma band severity at maximum contraction compared with placebo. The Food and Drug Administration (FDA) has approved Botox ® ...
Please provide your email address to receive an email when new articles are posted on . Results showed statistically significant improvement in platysma prominence after treatment with Botox Cosmetic ...
Please provide your email address to receive an email when new articles are posted on . Platysma prominence treatment with 26 to 36 units of onabotulinumtoxinA was well-tolerated and had a favorable ...
IRVINE, Calif., Oct. 18, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of BOTOX® Cosmetic for temporary improvement in the appearance ...
–All primary and secondary endpoints were met for second Phase 3 study (M21-310) and results were consistent with findings from first Phase 3 study (M21-309).–Results support onabotulinumtoxinA as a ...
Double board-certified facial plastic surgeon Dr. Benjamin C. Stong advances deep plane facelift surgery through comprehensive platysma release and resuspension designed to enhance neck contour and ...